TABLE 2.

HPV Type Prevalence Among CIN3+ in Prevaccine and Postvaccine Studies From the CDC Cancer Registry Sentinel Surveillance System

		Prevaccine 1993–2005a			Postvaccine 2014–2015b
Age y	HPV Typec	No. of Patients	Unweighted %	95% CI	No. of Patients	Weighted %		95% CI	P d
Total		n = 268			n = 348				.03*
	HPV 16, 18	180	67.2	61.3–72.5	227	67.8	61.3–73.7
	HPV 31, 33, 45, 52, 58	42	15.7	11.8–20.5	83	21.7	16.7–27.7
	Other oncogenic HPV	31	11.6	8.3–16.0	29	7.4	4.7–11.5
	Other HPV/HPV negative	15	5.6	3.4–9.0	9	3.1	1.3–7.0
15–24			n = 134			n = 71			.27
	HPV 16, 18	93	69.4	61.2–76.6	43	67.6	54.0–78.8
	HPV 31, 33, 45, 52, 58	19	14.2	9.3–21.1	21	21.4	12.7–33.7
	Other oncogenic HPV	13	9.7	5.8–15.9	5	8.4	3.1–21.0
	Other HPV/HPV negative	9	6.7	3.6–12.3	2	2.6	0.7–9.5
25–29			n = 87			n = 154			.47
	HPV 16, 18	58	66.7	56.2–75.7	106	72.1	62.4–80.0
	HPV 31, 33, 45, 52, 58	16	18.4	11.6–27.8	33	16.3	10.6–24.2
	Other oncogenic HPV	10	11.5	6.4–19.9	11	7.2	3.6–13.7
	Other HPV/HPV negative	3	3.4	1.2–9.7	4	4.5	1.5–12.9
30–34			n = 47			n = 123			.21
	HPV 16, 18	29	61.7	47.4–74.2	78	61.5	49.7–72.0
	HPV 31, 33, 45, 52, 58	7	14.9	7.4–27.7	29	30.2	20.2–42.4
	Other oncogenic HPV	8	17.0	8.9–30.1	13	7.1	3.7–13.1
	Other HPV/HPV negative	3	6.4	2.2–17.2	3	1.2	0.3–5.1

Abbreviations: CDC, Centers for Disease Control; CIN3+, cervical intraepithelial neoplasia grade 3 and adenocarcinoma in situ; FL, Florida; HI, Hawaii; HPV, human papillomavirus; IA, Iowa; ICC, invasive cervical cancer; KY, Kentucky; LA, Louisiana; MI, Michigan.

The data source was the CDC Cancer Registry Sentinel Surveillance System.

^aIncludes cases diagnosed from 1993–2005 from cancer registries in IA, LA, and MI; unweighted frequencies.

^bIncludes cases diagnosed from 2014–2015 from KY and LA cancer registries. Frequencies weighted for age and race/ethnicity.

^cOther oncogenic types include HPV 35, 39, 51, 56, 59, 66, and 68.

^dP values derived from generalized logit models adjusting for race/ethnicity.

^*P values considered statistically significant at P < .05.